scispace - formally typeset
G

Greg Conn

Researcher at Merck & Co.

Publications -  6
Citations -  961

Greg Conn is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vascular endothelial growth factor A & Growth factor. The author has an hindex of 3, co-authored 3 publications receiving 953 citations.

Papers
More filters
Journal ArticleDOI

Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor.

TL;DR: Glioma-derived vascular endothelial cell growth factor (GD-VEGF) is a 46-kDa dimeric glycoprotein mitogen with apparently greater specificity for vascular endothelium cells than the well-characterized fibroblast growth factors.
Journal ArticleDOI

Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor · Placenta Growth Factor Heterodimer

TL;DR: The existence of not only homodimer but also heterodimers clearly extends the similarity between the VEGF/PlGF and the homologous platelet-derived growth factor systems.
Journal ArticleDOI

Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line.

TL;DR: A growth factor that is mitogenic for vascular endothelial cells, with an ED50 of approximately 1 ng/ml, has been purified 170,000-fold to apparent homogeneity from tissue culture medium conditioned by a rat glioma-derived cell line, suggesting that this secretable growth factor could be readily available in the extracellular space under normal physiological conditions in vivo.
Journal ArticleDOI

Preliminary Safety of PDS0101 (Versamune +HPVmix) and Pembrolizumab Combination Therapy in Subjects with Recurrent/Metastatic Human Papillomavirus-16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)

TL;DR: In this paper , the combination of checkpoint inhibitor (CPI) and pembrolizumab is shown to be safe and well tolerated without evidence of enhanced or significant toxicity.
Journal ArticleDOI

Abstract B24: Development of targeted T-cell cancer immunotherapies based on a novel enantiomeric cationic lipid that promotes antigen cross-presentation and upregulation of type I interferons

TL;DR: Gandhapudi et al. as mentioned in this paper used the enantiomeric cationic lipid R-DOTAP nanoparticle platform (Versamune®) to promote cross presentation of multi-epitope human papilloma virus (HPV) antigens and upregulation of Type I interferons, leading to high levels of antigen-specific cytolytic polyfuctional CD8+ T-cells in vivo and complete regression of TC-1 tumors in preclinical models.